Boston Scientific Corporation (NYSE: BSX) is a global medical device company focused on cardiovascular, rhythm management, and minimally invasive therapies. Shares recently traded around $95 per share, giving the company a market value of roughly $141B.
Boston Scientific has benefited from steady procedure demand and expanding margins across several core product categories. Reviewing who owns the stock and how insiders are trading helps show how large investors are approaching the company today.
Who Are Boston Scientific’s Top Shareholders?
Boston Scientific’s shareholder base is led by large institutional investors, particularly passive asset managers that tend to hold through market cycles. Active managers adjusted positions in both directions, reflecting a mix of confidence and valuation sensitivity.
- The Vanguard Group: 137.6M shares (9.28%), ~$13.1B value. Added ~1.09M shares (+0.80%).
- Fidelity Management & Research: 90.6M shares (6.11%), ~$8.6B value. Cut ~8.85M shares (−8.90%).
- BlackRock Institutional Trust: 79.6M shares (5.37%), ~$7.6B value. Added ~1.41M shares (+1.81%).
- State Street Investment Management: 64.9M shares (4.38%), ~$6.2B value. Cut ~266k shares (−0.41%).
- PRIMECAP Management: 33.1M shares (2.23%), ~$3.2B value. Cut ~1.56M shares (−4.50%).
- Geode Capital Management: 32.7M shares (2.21%), ~$3.1B value. Added ~266k shares (+0.82%).
- Capital World Investors: 26.6M shares (1.80%), ~$2.5B value. Cut ~1.88M shares (−6.58%).
- Managed Account Advisors: 23.2M shares (1.56%), ~$2.2B value. Added ~1.11M shares (+5.03%).
- The Bollard Group: 19.7M shares (1.33%), ~$1.9B value. Cut ~346k shares (−1.72%).
- Norges Bank Investment Management: 19.5M shares (1.31%), ~$1.9B value. Cut ~275k shares (−1.39%).
For investors, the presence of large passive holders provides ownership stability, while mixed moves among active managers suggest differing views on valuation rather than a broad shift in confidence.
Hedge Fund Highlights
One notable move last quarter came from Parnassus Investments, founded by Jerome Dodson, which significantly increased its position in Boston Scientific to roughly $672M value, suggesting the firm may be leaning more positively on the company’s long term medical device growth profile.
Jane Street Group, co founded by Rob Granieri, also expanded its exposure, now holding close to $291M value in Boston Scientific shares. The move appears consistent with increased positioning following continued procedural demand strength.
Squarepoint Ops LLC, led by Michael Platt, boosted its Boston Scientific stake to approximately $179M value, reflecting growing interest from multi strategy funds as the company continues to deliver steady earnings growth.
Meanwhile, Magnetar Financial, founded by Alec Litowitz, raised its Boston Scientific position to nearly $6.8M value, adding to a broader pattern of hedge funds selectively increasing exposure rather than exiting the stock.
For investors, hedge fund activity appears balanced but constructive, with additions suggesting interest while position sizing remains measured.
Track the top shareholders of over 50,000 global stocks (It’s free) >>>
Boston Scientific’s Recent Insider Trades
Recent filings show a mix of sales, equity awards, and administrative entries, with selling activity outweighing buying.
- Arthur C. Butcher (Officer/Director): Sold ~34,600 shares across multiple trades at prices between ~$17 and ~$102; also recorded offsetting share receipts at lower prices.
- Joseph Michael Fitzgerald (Officer): Sold over 110,000 shares at prices near ~$99 to ~$101; also recorded matching share awards.
- Ellen M. Zane (Director): Sold 12,891 shares at ~$98.28.
- Miriam O’Sullivan (Officer): Sold 260 shares at $0, which appears administrative.
- Multiple Form 144 filings: Reflected zero net share changes.
For investors, insider activity appears cautious, with many transactions paired with equity awards or administrative filings, making it difficult to draw strong conviction signals.
See recent insider trade data for over 50,000 global stocks (It’s free) >>>
What the Ownership & Insider Trade Data Tell Us
Boston Scientific’s ownership remains institutionally driven, anchored by large passive investors and supported by selective hedge fund additions. Insider activity leans toward selling, though the structure of many trades suggests compensation related timing rather than a clear shift in outlook.
For investors, the overall picture points to continued confidence in Boston Scientific’s long term business quality, while positioning across institutions and insiders appears measured as the stock trades near recent highs.
Value Any Stock in Under 60 Seconds (It’s Free)
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
